Back to results
US 2026/0152805 A1Published application
Methods of treating cancer
AssigneeNantCell, Inc.
InventorsSadanand VODALA, Andrew NGUYEN, Charles Joseph VASKE, Shahrooz RABIZADEH
Life of this patent
Estimating the term…
Abstract
Multimodal cancer immunotherapy is a combination of cancer immunotherapies used to treat cancer in patients. T cell receptor diversity is used as a component of a method to treat cancer involving cancer therapy, including multimodal cancer immunotherapy.
Claims14
1-19. (canceled)
A method of increasing T cell receptor (TCR) diversity in a patient having cancer, the method comprising administering a multimodal cancer immunotherapy to the patient, wherein the multimodal cancer immunotherapy comprises:
- a. an NK cell selected from the group consisting of aNK, haNK, taNK, and t-haNK;
- and
- b. two or more immunotherapies selected from the group consisting of a viral vector expressing an antigen, a yeast immunotherapy, an immune checkpoint inhibitor, and an IL-15 superagonist;
- wherein the TCR diversity in blood from the patient increases at least three-fold between a first time point of the multimodal cancer immunotherapy and a second time point of the multimodal cancer immunotherapy at least two months after the first time point.
1 more element
Dependencies are inferred from the claim text.